Try our Advanced Search for more refined results
Life Sciences
-
December 16, 2025
Va. Judge Advances Most Claims In Stelara Antitrust Case
A Virginia federal judge has allowed health insurer CareFirst's anticompetition and patent fraud claims against Johnson & Johnson to move forward in a case alleging anticompetitive behavior in relation to the immunosuppressive drug Stelara, while letting the pharmaceutical giant escape some claims of misrepresentation.
-
December 16, 2025
Trump Executive Order Calls Fentanyl A 'WMD'
President Donald Trump has declared fentanyl a "weapon of mass destruction," according to an executive order that explicitly calls on the military to respond to "chemical incidents in the homeland."
-
December 16, 2025
The Most Important Healthcare And Life Science Deals Of 2025
Attorneys taking stock of 2025 spoke to Law360 about the most important deals of the year, including Pfizer’s high-profile acquisition of Metsera and transactions in outpatient services and gene therapy.
-
December 16, 2025
Trends That Shaped Healthcare Dealmaking In 2025
With 2025 coming to a close, Law360 Healthcare Authority asked attorneys focused on healthcare deals for their take on the trends that influenced dealmaking over the last 12 months.
-
December 16, 2025
Merck Sued Over Time Rounding, OT Averaging At NC Plant
A Merck manufacturing facility in North Carolina rounded workers' time to short them on pay, averaged out overtime across two weeks and fired an operator technician because of his sleep apnea, the worker told a federal court in a proposed class and collective action against the pharmaceutical giant.
-
December 16, 2025
Jury Says Magnolia Medical Is Owed $1.6M After Patent Trial
A Delaware federal jury on Tuesday morning found that Magnolia Medical Technologies Inc. is entitled to nearly $1.6 million after Kurin Inc. infringed its patents tied to devices meant for drawing blood.
-
December 16, 2025
5 Big Litigation Developments Out Of Georgia In 2025
It was a busy year for courts in Georgia, with a federal judge ordering the state's corrections system to continue providing hormone therapy to transgender people in prison, and prosecutors deciding to drop the historic racketeering case against President Donald Trump and his allies. Here, Law360 recaps the biggest legal developments to come out of Peach State courts in 2025.
-
December 16, 2025
Another Dechert IP Atty Leaves, This Time For Morgan Lewis
Morgan Lewis LLP has added another departing member of the Dechert LLP intellectual property team, who joins the firm in Boston after Dechert's global intellectual property practice co-chair, two partners, and a total of 30 professionals moved to Cooley LLP last week.
-
December 16, 2025
Medical Device Maker Zynex Hits Ch. 11 With Sale Plans
Zynex Inc., a pain management medical device maker, filed for bankruptcy protection in Texas with at least $66.7 million in debt and plans to sell the business backed by a stalking horse bid from its creditors.
-
December 15, 2025
Smartwatch Giants Sued Over Fall Detection Patents
A company that makes medical alert watches for the elderly has sued Apple, Samsung, Google and Garmin in federal court and the U.S. International Trade Commission, alleging that the fall detection features in their smartwatches infringe two patents.
-
December 15, 2025
States Fight Sandoz Bid To Argue Duplication In Generics Row
Multiple attorneys general have told a Connecticut federal court that Sandoz Inc. and Fougera Pharmaceuticals Inc. can't claim the states' grievances over allegations of price fixing are duplicative of claims that were already settled, since there are some claims and forms of relief that only state plaintiffs can seek.
-
December 15, 2025
DOJ Raises Accreditation Concerns In Vet School Case
The U.S. Department of Justice waded into a Tennessee veterinary school's antitrust case challenging the American Veterinary Medical Association's accreditation requirements, raising concerns about the risk posed by professional groups that play gatekeeping functions.
-
December 15, 2025
Ohio Gov. To Designate Synthetic Kratom Extract Illegal Drug
Ohio Gov. Mike DeWine is looking to immediately ban synthetic kratom compounds while simultaneously seeking to either ban or heavily regulate the active ingredient in "natural kratom," citing serious public health concerns.
-
December 15, 2025
Formula Suits An 'Undue Burden' On Cook County, Panel Says
An Illinois appellate court Friday agreed with Abbott Laboratories that 23 lawsuits alleging the company failed to warn of important risks associated with infant formulas and caused premature babies to develop necrotizing enterocolitis should not have been filed in Cook County, where the infants at the center of those cases were not born and have never lived.
-
December 15, 2025
USPTO Replaces Denver Office With Center In Montana
Montana has been picked by the U.S. Patent and Trademark Office to be the first state to oversee community outreach in the area formerly serviced by the now-shuttered Rocky Mountain Regional Outreach Office in Denver.
-
December 15, 2025
Cencora Pays $5B For Majority Stake Of OneOncology
Pharmaceutical company Cencora Inc. unveiled plans Monday to acquire a majority stake in cancer care company OneOncology for $5 billion, buying interest from private equity shop TPG in a deal built by three law firms.
-
December 15, 2025
Connecticut 'Likely' To Settle Generic Drug Price Cap Dispute
A pharmaceutical industry trade group and the state of Connecticut have signaled their intent to settle a feud over the interpretation of the state's generic drug price cap law, and a federal judge gave them until Monday to say more about their plan.
-
December 15, 2025
Fed. Circ. Won't Revive Bard Patents In AngioDynamics Row
The Federal Circuit on Monday refused to revive claims in C.R. Bard patents on implanted catheter receptacles that were challenged by AngioDynamics, backing a Delaware federal court's finding that the claims were anticipated.
-
December 15, 2025
Blank Rome Hires Baker McKenzie Litigator In DC
Blank Rome LLP has hired a Baker McKenzie litigator who focuses his practice on technology, life sciences, aerospace, government contracts and energy industry-related matters to join the team in Washington, D.C., as a partner, the firm announced Monday.
-
December 15, 2025
The Top Patent Decisions Of 2025
The Federal Circuit decided its first en banc utility patent case in years and expanded who can use the U.S. International Trade Commission, while both the appeals court and U.S. Patent and Trademark Office took on the eligibility of AI patents. Here's a look at the top patent decisions of 2025.
-
December 15, 2025
PTAB Creates New Prehearing Conference For AIA Reviews
The Patent Trial and Appeal Board has rolled out a change to its trial practice guide that will create a new prehearing conference 15 days prior to oral hearings under the America Invents Act in cases implemented by the U.S. Patent and Trademark Office director.
-
December 15, 2025
High Court Won't Review Doctor 'Upcoding' Acquittal Decision
The U.S. Supreme Court said Monday that it won't review a decision allowing a retrial of a Maryland doctor who was initially found guilty of a COVID-19 testing scheme but then secured an acquittal.
-
December 15, 2025
Supreme Court Declines Cannabis Ban Review
The U.S. Supreme Court on Monday declined to hear a case challenging the federal marijuana ban, leaving in place a high court precedent that has governed cannabis policy for 20 years.
-
December 15, 2025
Supreme Court Turns Down Entresto Patent Fight
The U.S. Supreme Court on Monday rejected a petition from MSN Pharmaceuticals Inc. claiming the Federal Circuit improperly applied what is known as after-arising technology when reviving a patent covering Novartis Pharmaceuticals Corp.'s blockbuster cardiovascular drug Entresto.
-
December 15, 2025
McDermott-Led Sobi To Buy US Gout Specialist For $1.5B
Swedish biopharma company Swedish Orphan Biovitrum AB said Monday that it has agreed to acquire Arthrosi Therapeutics Inc., a specialist in treatment for gout, for up to $1.5 billion in a deal guided by McDermott.
Expert Analysis
-
Associates Can Earn Credibility By Investing In Relationships
As the class of 2025 prepares to join law firms this fall, new associates must adapt to office dynamics and establish credible reputations — which require quiet, consistent relationship-building skills as much as legal acumen, says Kyle Forges at Bast Amron.
-
Puzzling Out When Similar Insurance Claims Are Related
A recent decision in Virginia federal court shows that more than identical allegations of negligent business practices across two lawsuits may be necessary to satisfy the strict definition of relatedness under claims-made liability insurance policies, say attorneys at Hunton.
-
A Shifting Trend In FDA Form 483 Disclosure Obligations
A New York federal court's Checkpoint Therapeutics decision extends a recent streak of dismissals of securities class actions alleging that pharmaceutical companies failed to disclose U.S. Food and Drug Administration Form 483 inspection reports, providing critical guidance for companies during the FDA approval process, say attorneys at Alston & Bird.
-
Trending At The PTAB: IPR Memo And Its Fed. Circ. Backdrop
There are new rules for when and how evidence other than patents or printed publications can be considered in inter partes reviews, and while this change is intended to reflect current Federal Circuit precedent, the U.S. Patent and Trademark Office's memo seems to acknowledge tension with last month's Shockwave decision, say attorneys at Finnegan.
-
Lessons From 7th Circ.'s Deleted Chat Sanctions Ruling
The Seventh Circuit’s recent decision in Pable v. Chicago Transit Authority, affirming the dismissal of an ex-employee’s retaliation claims, highlights the importance of properly handling the preservation of ephemeral messages and clarifies key sanctions issues, says Philip Favro at Favro Law.
-
Breaking Down The Proposed Hemp Bill
A proposed bill in the U.S. House of Representatives, recently approved by the House Appropriations Committee, contains a rider that would significantly change the definition of hemp and dramatically reshape the current hemp-derived product market, say attorneys at King & Spalding.
-
Assessing Federal Securities Class Action Stats In '25 So Far
The settlement amount as a percentage of damages in securities class actions has continued to decline in the first half of 2025, a trend that may be important for assessing exposure and risk in future securities litigation, say analysts at Analysis Group.
-
Series
Quilting Makes Me A Better Lawyer
Turning intricate patterns of fabric and thread into quilts has taught me that craftsmanship, creative problem-solving and dedication to incremental progress are essential to creating something lasting that will help another person — just like in law, says Veronica McMillan at Kramon & Graham.
-
How Agentic AI Is Testing The Limits Of Patent Law
While a recent Swiss court ruling suggests that human-centric rules regarding inventorship will likely remain in place for the near future, it captures a core tension confronting patent systems worldwide as the technology producing patent-worthy ideas is becoming increasingly autonomous, says Matthew Carey at Marshall Gerstein.
-
How To Prep For Potential Passage Of SAFER Banking Act
The Secure and Fair Enforcement Regulation, or SAFER, Banking Act, could fundamentally reshape how financial institutions interact with cannabis businesses, so operators that move now to get their house in order will be best positioned to capitalize if and when change comes, says Alex Leonowicz at Howard & Howard.
-
A Former PTAB Judge Weighs The End Of Remote Hearings
Former Patent Trial and Appeal Board Judge Amanda Wieker, now at McGuireWoods, examines the costs and benefits of the PTAB's impending in-person hearing requirement, and offers suggestions for making the most out of this new regime.
-
The Future Of Lab-Test Regs After FDA Rescinds Rule
The U.S. Food and Drug Administration recently rescinded its laboratory-developed tests rule in response to a Texas federal court decision this spring, reinforcing a separation of authority between the FDA and the Centers for Medicare & Medicaid Services, and calling into question the FDA's role in overseeing such tests without congressional action, say attorneys at Venable.
-
SDNY Ruling Reinforces Joint Steering Committee Obligations
The recent Southern District of New York decision in ChemImage v. Johnson & Johnson makes joint steering committees a valuable tool in strategic relationships, as provisions for such committees can now be wielded to demand attention to core issues, say Lisa Bernstein at the University of Chicago Law School, and Reginald Goeke and Brad Peterson at Mayer Brown.
-
What 2 Profs Noticed As Transactional Law Students Used AI
After a semester using generative artificial intelligence tools with students in an entrepreneurship law clinic, we came away with numerous observations about the opportunities and challenges such tools present to new transactional lawyers, say professors at Cornell Law School.
-
What Patent Claim 'Invalidity' Means In Different Forums
A recent Federal Circuit order allowing a patent suit to proceed despite similar claims being invalidated in an inter partes review underscores how fractured the patent litigation landscape has become, leading to critical nuances in how district courts, the U.S. International Trade Commission and Patent Trial and Appeal Board treat invalidity, says Jason Hoffman at BakerHostetler.